TrialPath
Recruiting

Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

NCT07808151 · Solstice Oncology, Inc.
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 2, Open-Label, Multicenter, Randomized Trial Evaluating the Efficacy and Safety of Different Schedules of Neoadjuvant Pembrolizumab and Porustobart in Patients With Resectable pMMR/MSS Colon Cancer
About this study
The goal of this clinical trial is to learn if giving two medicines together, porustobart and pembrolizumab, before surgery can treat a common type of colon cancer called microsatellite stable (MSS) colon cancer in adults. This type of cancer can be removed with surgery and has not spread to other parts of the body. Both medicines work by helping the immune system fight cancer. The main questions this study wants to answer: How well do the medicines destroy the cancer before surgery? What side effects do participants have when taking the medicines? Researchers will compare two groups to see which treatment schedule works better and is safer. Both groups get pembrolizumab. One group gets one dose of porustobart (Day 1 only), and the other group gets two doses (Day 1 and Day 22). Participants will: Complete certain tests and procedures to make sure they are eligible Get the medicines through a vein on Day 1 and Day 22 then have surgery 6-9 weeks after starting treatment Return for checkups and tests every 6 months for up to 3 years after surgery
Eligibility criteria
Inclusion Criteria: ≥18 years of age at consent Adenocarcinoma of the colon (rectosigmoid considered non-rectal); pMMR/MSS status Any T3 or T4, N any, M0; disease amenable to surgical resection ECOG Performance Status 0-1 Adequate tumor tissue sample with associated pathology report Adequate hematologic, hepatic, and renal function Reproductive status/contraception requirements per protocol Exclusion Criteria: Investigational agent within 3 weeks of first dose Imminent or urgent need for surgery Prior treatment with ICIs targeting CTLA-4, PD-1, or PD-L1 Systemic corticosteroid/immunosuppressive therapy within 1 week of first dose (exceptions apply) History of severe hypersensitivity to a fully human mAb; interstitial lung disease; pneumonitis requiring corticosteroids Active or history of autoimmune disease requiring systemic treatment within 2 years Major surgery within 4 weeks of first dose; active infection requiring treatment
Study design
Enrollment target: 100 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-11-30
Estimated completion: 2029-09-30
Last updated: 2026-11-12
Interventions
Drug: PembrolizumabDrug: Porustobart
Primary outcomes
  • • Major Pathologic Response (MPR) rate by Blinded Independent Pathologic Review (BIPR) (Assessed from surgical resection specimen (surgery occurs Day 42-Day 63, i.e., approximately Week 6-Week 9 after first dose))
Sponsor
Solstice Oncology, Inc. · industry
Contacts & investigators
ContactMedical Monitor · contact · SOL1-201@solsticeoncology.com · 617-982-2331
All locations (30)
Investigator SiteRecruiting
Los Angeles, California, United States
Investigator SiteNot Yet Recruiting
Tampa, Florida, United States
Investigator SiteNot Yet Recruiting
Chicago, Illinois, United States
Investigator SiteRecruiting
Baltimore, Maryland, United States
Investigator SiteNot Yet Recruiting
Boston, Massachusetts, United States
Investigator SiteNot Yet Recruiting
New York, New York, United States
Investigator SiteNot Yet Recruiting
New York, New York, United States
Investigator SiteNot Yet Recruiting
New York, New York, United States
Investigator SiteRecruiting
Cleveland, Ohio, United States
Investigator SiteNot Yet Recruiting
Nashville, Tennessee, United States
Investigator SiteRecruiting
Seattle, Washington, United States
Investigator SiteNot Yet Recruiting
Anderlecht, Belgium
Investigator SiteNot Yet Recruiting
Bonheiden, Belgium
Investigator SiteNot Yet Recruiting
Ghent, Belgium
Investigator SiteNot Yet Recruiting
Leuven, Belgium
Investigator SiteNot Yet Recruiting
Liège, Belgium
Investigator SiteNot Yet Recruiting
Ostend, Belgium
Investigator SiteNot Yet Recruiting
Woluwe-Saint-Lambert, Belgium
Investigator SiteNot Yet Recruiting
Milan, Italy
Investigator SiteNot Yet Recruiting
Naples, Italy
Investigator SiteNot Yet Recruiting
Pisa, Italy
Investigator SiteNot Yet Recruiting
Amsterdam, Netherlands
Investigator SiteNot Yet Recruiting
Barcelona, Spain
Investigator SiteNot Yet Recruiting
L'Hospitalet de Llobregat, Spain
Investigator SiteNot Yet Recruiting
Madrid, Spain
Investigator SiteNot Yet Recruiting
Aberdeen, United Kingdom
Investigator SiteNot Yet Recruiting
Cardiff, United Kingdom
Investigator SiteNot Yet Recruiting
Glasgow, United Kingdom
Investigator SiteNot Yet Recruiting
Leeds, United Kingdom
Investigator SiteNot Yet Recruiting
London, United Kingdom
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer · TrialPath